Posted by Michael Wonder on 24 Apr 2021
Highlights from the April 19-22 CHMP meeting
23 April 2021 - EMA’s CHMP recommended eight medicines for approval at its April 2021 meeting.
The Committee gave a positive opinion for Enspryng (satralizumab) for the treatment of neuromyelitis optica spectrum disorders in patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.
Evkeeza (evinacumab) was granted a positive opinion by the Committee for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia.
